Home  |  Site Map  |  Glossary  | Contact
MAY 3 QLT Announces First Quarter 2012 Results
   
APR 16 QLT Announces the Appointment of Christopher Muller as Chief Commercial Officer
   
APR 2 Media Advisory: QLT Announces QLT091001 Presentation at ARVO
   
MAR 19 QLT Receives Orphan Drug Designation for Visudyne for Treatment of Central Serous Chorioretinopathy
   
  2012 Proxy Materials and Annual Report
The Proxy Materials for the Annual Meeting of Shareholders to be held on May 24, 2012 are now available. For the 2012 Proxy Statement and our Annual Report for the fiscal year ended December 31, 2011, please click here.
   
  QLT Annual Meeting of Shareholders
On May 24, 2012, QLT will hold its Annual Meeting of Shareholders at our headquarters in Vancouver, British Columbia. For more information, please see QLT's most recent proxy statement. For directions to the meeting, please click here.
   
 

QLT Conference Call - May 10
QLT hosted a webcast conference call to discuss data from the Phase 1b trial of QLT091001 in subjects with RP due to RPE65 and LRAT mutations on Thursday, May 10, 2012. To listen to a replay of the webcast, please click here.    For presentation slides, click here.

 
HEAD OFFICE: QLT Inc., 887 Great Northern Way, Suite 101, Vancouver, BC, Canada, V5T 4T5 | t 800.663.5486
Copyright © 2000-2009 QLT Inc. Legal Terms for use of site and Privacy Policy | Disclaimer
Vancouver Web Design by Graphically Speaking
 
Employee Login
 
'ss